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Abstract
Huntington’s	disease	(HD)	is	a	progressive	neurodegenerative	disorder	caused	by	an	
expanded	CAG	repeat	within	 the	huntingtin	 (HTT)	 gene.	The	Q140	and	HdhQ150	
knock‐in	 HD	 mouse	 models	 were	 generated	 such	 that	 HdhQ150	 mice	 have	 an	  
expanded	CAG	repeat	inserted	into	the	mouse	Htt	gene,	whereas	in	the	Q140s,	mouse	
exon 1 Htt	was	replaced	with	a	mutated	version	of	human	exon	1.	By	standardizing	
mouse	strain	background,	breeding	to	homozygosity	and	employing	sensitive	behav-
ioral	tests,	we	demonstrate	that	the	onset	of	behavioral	phenotypes	occurs	earlier	
in	the	Q140	than	the	HdhQ150	knock‐in	mouse	models	and	that	huntingtin	 (HTT)	 
aggregation	appears	earlier	 in	the	striata	of	Q140	mice.	We	have	previously	found	
that	the	incomplete	splicing	of	mutant	HTT	from	exon	1	to	exon	2	results	in	the	pro-
duction	of	a	small	polyadenylated	transcript	that	encodes	the	highly	pathogenic	mu-
tant	HTT	exon	1	protein.	In	this	report,	we	have	identified	a	functional	consequence	
of	the	sequence	differences	between	these	two	models	at	the	RNA	level,	in	that	the	
level	of	incomplete	splicing,	and	of	the	mutant	exon	1	HTT	protein,	are	greater	in	the	
brains	of	Q140	mice.	While	differences	in	the	human	and	mouse	exon	1	HTT	proteins	
(e.g.,	proline	rich	sequences)	could	also	contribute	to	the	phenotypic	differences,	our	
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1  | INTRODUC TION
Huntington’s	 disease	 (HD)	 is	 an	 autosomal	 dominant,	 progressive,	
neurodegenerative	 disorder	 caused	 by	 a	 CAG	 repeat	 expansion	
within	exon	1	of	the	huntingtin	gene	(HTT),	that	encodes	a	polyglu-
tamine	(polyQ)	tract	 in	the	HTT	protein	 (Bates	et	al.,	2015).	Overt	
symptoms	typically	appear	in	midlife	and	include	psychiatric	symp-
toms,	 cognitive	 deficits,	 chorea,	 and	 other	 movement	 disorders,	
sleep	disturbances	and	weight	loss.	HD	patients	develop	character-
istic	neuropathology	involving	whole	brain	atrophy,	loss	of	neurons	
in	the	striatum	(Vonsattel	&	DiFiglia,	1998),	cortex	and	other	brain	
regions,	and	the	deposition	of	HTT	inclusions	(DiFiglia	et	al.,	1997;	
Gutekunst	et	al.,	1999).	Therapeutic	 interventions	that	modify	the	
devastating	and	fatal	course	of	this	disease	have	yet	to	be	developed.
Mouse	models	of	HD	have	provided	invaluable	insights	into	the	
pathogenic	basis	of	this	disease.	Transgenic	mice	that	express	an	N‐ 
terminal	fragment	of	human	HTT	(Mangiarini	et	al.,	1996;	Schilling	et	al.,	 
1999)	 develop	 HD‐related	 phenotypes	 with	 an	 early	 onset	 that	
progresses	 rapidly	and	 leads	 to	a	considerably	 shortened	 lifespan.	
In	 contrast,	 knock‐in	models,	 in	which	 the	HD	mutation	has	 been	
introduced	into	the	mouse	Htt	gene,	more	accurately	represent	the	
genetic	basis	of	HD	with	the	mutation	being	expressed	in	its	appro-
priate	genomic	and	protein	context	 (Menalled,	2005).	The	analysis	
of	two	HD	knock‐in	models	suggests	that	sequence	differences	at	
the	genetically	altered	loci	might	modify	the	age	of	onset	and	pro-
gression	of	HD‐related	phenotypes	 in vivo.	The	HdhQ150	line	was	
created	 by	 replacing	 the	mouse	 (CAG)2CAA(CAG)4	 sequence	with	
an	 expanded	CAG	 repeat,	without	 any	 other	modifications	 to	 the	
locus	(Lin	et	al.,	2001).	In	contrast,	in	the	Q140	line,	exon	1	of	mouse	
Htt	was	replaced	with	exon	1	of	human	HTT	carrying	an	expanded	
CAG	repeat	(Hickey	et	al.,	2008;	Menalled,	Sison,	Dragatsis,	Zeitlin,	
&	Chesselet,	2003).	The	Q140	and	HdhQ150	mice	were	generated	
by	genetically	modifying	129/Sv	and	129/Ola	embryonic	stem	cells,	
respectively,	 injecting	 these	 into	 C57BL/6J	 blastocysts	 (Lin	 et	 al.,	
2001;	Menalled	et	al.,	2003)	and	backcrossing	to	C57BL/6J,	to	pro-
duce	mice	with	a	mixed	strain	background.
Robust	 behavioral	 deficits	 have	been	detected	 in	homozygous	
Q140	mice	on	a	mixed	strain	background	from	as	early	as	1	month	
of	age	(Dorner,	Miller,	Barton,	Brock,	&	Rebec,	2007;	Hickey	et	al.,	
2008;	Menalled	et	al.,	2003;	Rising	et	al.,	2011).	A	comprehensive	
analysis	 of	 the	HdhQ150	mice	 using	 the	 same	 tests	 has	 not	 been	
performed,	however,	the	available	data	indicate	that	behavioral	phe-
notypes	present	much	later	(Brooks,	Higgs,	Jones,	&	Dunnett,	2012;	
Heng,	 Tallaksen‐Greene,	 Detloff,	 &	 Albin,	 2007;	 Lin	 et	 al.,	 2001;	
Woodman	 et	 al.,	 2007).	 These	 data	 suggest	 that	 sequence	 differ-
ences	 in	 the	Q140	and	HdhQ150	mutant	Htt	 genes	 result	 in	 con-
siderable	differences	 in	 the	onset	of	behavioral	deficits.	However,	
comparison	of	the	phenotypes	of	these	mice	has	been	confounded	
by	the	fact	that	they	were	analyzed	on	different	strain	backgrounds	
and	in	different	laboratories,	where	husbandry	practices	and	the	be-
havioral	tests	used	had	not	been	standardized.	Importantly,	the	most	
sensitive	tests	used	to	detect	early	behavioral	deficits	in	the	Q140	
line	have	not	been	used	for	HdhQ150	mice.
We	 reasoned	 that	 if	 differences	 in	 the	 onset	 of	 behavioral,	 neu-
ropathological,	 and	 molecular	 deficits	 could	 be	 identified,	 this	 might	
uncover	factors	that	modify	the	onset	of	HD	symptoms	and	identify	ther-
apeutic	targets.	In	order	to	directly	compare	these	knock‐in	models,	we	
generated	Q140	and	HdhQ150	C57Bl/6J	congenic	lines,	bred	them	to	
homozygosity,	and	systematically	tested	them	in	parallel	using	identical,	
sensitive	assays	of	behavioral,	pathological	and	molecular	phenotypes,	
performed	at	the	same	ages	within	the	same	laboratory.	We	show	that	
behavioral	deficits	occur	earlier	in	Q140	as	compared	to	HdhQ150	mice	
and	that	this	is	associated	with	an	earlier	evidence	of	HTT	aggregation	
in	the	brain.	We	also	show	increased	levels	of	the	incompletely	spliced	
Httexon1	transcript	that	encodes	the	highly	pathogenic	exon	1	HTT	pro-
tein	(Neueder	et	al.,	2017;	Sathasivam	et	al.,	2013)	in	Q140	as	compared	
to	HdhQ150	C57BL/6J	congenic	lines.	Our	work	suggests	that	increased	
production	of	the	mutant	exon	1	HTT	protein	in	Q140	mice	may	contrib-
ute	to	an	earlier	phenotype	onset	and	supports	the	design	of	therapeu-
tics	that	decrease	the	levels	of	the	small	Httexon1	transcript.
data	indicate	that	the	incomplete	splicing	of	HTT	and	approaches	to	lower	the	levels	
of	the	exon	1	HTT	transcript	should	be	pursued	as	therapeutic	targets.
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Significance
Knock‐in	mouse	models	most	accurately	reflect	the	genetic	
basis	of	Huntington’s	disease,	but	have	been	generated	by	
different	genetic	modification	strategies.	Here	we	show	that	
the	onset	of	behavioral	phenotypes	and	the	striatal	deposi-
tion	of	HTT	aggregates	occurs	earlier	 in	 the	Q140	than	 in	
the	HdhQ150	model.	This	correlated	to	increased	levels	of	
the	incompletely	spliced	Httexon1	transcript	and	the	highly	
aggregation	prone	and	pathogenic	exon	1	HTT	protein	that	
it	encodes.	Our	results	highlight	the	importance	of	develop-
ing	therapeutic	strategies	to	lower	levels	of	exon	1	HTT.
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2  | MATERIAL S AND METHODS
2.1 | Animals
At	 UCLA,	 all	 procedures	 on	mice	were	 carried	 out	 in	 accordance	
with	 the	NIH	Guide	 for	 the	 Care	 and	 Use	 of	 Laboratory	 Animals	
(NIH	 Publications	 No.	 80‐23)	 revised	 1996,	 and	 approved	 by	 the	
UCLA	Institutional	Animal	Care	and	Use	Committee.	In	the	United	
Kingdom,	all	animal	care	and	procedures	were	performed	in	compli-
ance	with	United	Kingdom	Home	Office	 regulations	 (Animals	 and	
Scientific	Procedures	Act	1986)	and	were	approved	by	the	University	
Ethical	Review	Process	Committee.
2.1.1 | Q140 and HdhQ150 knock‐in mice
Homozygous	Q140	and	HdhQ150	knock‐in	mice	were	backcrossed	
to	C57Bl/6J	mice	(JAX	Stock#	000664)	for	ten	successive	genera-
tions	to	generate	>99.9%	genetically	pure	C57Bl/6J	congenic	lines,	
which	was	confirmed	by	single	nucleotide	polymorphism	(SNP)	anal-
ysis.	Mice	were	bred	in	animal	facilities	operated	by	UCLA	Division	
of	Laboratory	Animal	Medicine	(DLAM).	For	each	experiment,	mice	
in	all	experimental	groups	were	housed	under	identical	conditions.	
Mice	not	undergoing	behavioral	testing	were	housed	in	the	DLAM	
facility,	 under	 standard	 light	 cycle	 conditions	 (12	 hr	 on/off,	 with	
lights	off	at	6	p.m.),	where	they	were	group	housed	 (2–4	mice	per	
cage),	with	the	exception	of	some	older	mice	(typically	~12	months)	
that	were	singly	housed	as	a	result	of	attrition	of	cage	mates.	Mice	
were	fed	a	diet	of	standard	mouse	chow	(Harlan‐Teklad)	and	DLAM	
facility	cages	had	corncob	bedding	and	several	cotton	nestlets	per	
cage.	 All	 mice	 that	 were	 used	 for	 behavioral	 analysis	 were	 trans-
ferred	from	the	UCLA	DLAM	facility	to	a	reverse	light	cycle	facility	
(12	hr	on/off,	with	 lights	off	at	10	a.m.),	1	week	before	behavioral	
testing	began.	Here,	 they	were	group	housed	 (2–4	mice	per	cage),	
with	standard	bedding	consisting	of	shredded	wood	chips,	and	mate-
rial	for	nest‐building	(Nestlets,	Ancare,	NY,	USA),	and	had	ad	libitum	
access	 to	water	 and	 standard	 rodent	diet	 (NIH‐31	modified	7013,	
Harlan).	Room	temperature	in	both	mouse	facilities	was	23°C	±	2°C	
and	relative	humidity	was	~60%;	these	values	being	recorded	dur-
ing	a	daily	animal	check.	Behavioral	testing	was	performed	between	
1.00	and	5.00	p.m.	during	the	dark	phase,	under	red	light,	in	a	speci-
fied	room	for	behavioral	experiments	adjacent	to	the	animal	housing	
room.
Tail	tips	were	biopsied	for	genotyping	between	14	and	21	days	of	
age	and	mice	were	weaned	by	21	days	of	age.	Q140	mice	genotyping	
was	performed	as	described	in	Hickey	et	al.	(2008)	and	HdhQ150	mice	
genotyping	was	performed	as	described	in	Heng	et	al.	(2007).	Tail	bi-
opsies	were	again	collected	when	mice	were	euthanized	for	re‐geno-
typing.	Tail	DNA	from	a	subset	of	mice	was	used	for	CAG	repeat	length	
analysis	 at	 Laragen,	 Inc.	 (Culver	 City,	 CA).	 For	 Q140	 homozygotes	
(n	=	18),	the	longer	allele	had	a	mean	of	127.2	±	9.0	(SD)	CAGs,	while	
the	shorter	allele	had	a	mean	of	119.2	±	4.6	(SD)	CAGs.	For	HdhQ150	
homozygotes	(n	=	17),	the	longer	allele	had	a	mean	of	141.1	±	8.0	(SD)	
CAGs,	while	the	shorter	allele	had	a	mean	of	128.4	±	8.0	(SD)	CAGs.	
Therefore,	 the	 HdhQ150	 mice	 had	 significantly	 longer	 CAG	 repeat	
lengths	 than	 Q140	 mice	 (two‐tailed	 Student’s	 t	 tests,	 larger	 allele:	
p	=	0.00004,	smaller	allele:	p	=	0.0001).
For	each	experiment,	all	mice	in	each	experimental	group	were	
euthanized	and	tissue	collected	at	the	same	time	of	day.	Mice	used	
for	behavioral	analysis	were	euthanized	during	the	dark	phase	of	the	
diurnal	cycle,	1–3	hr	after	lights	off.	All	other	mice	were	euthanized	
during	the	light	phase	of	the	diurnal	cycle,	5–8	hr	after	lights	on.
2.1.2 | zQ175 and zQ175DN knock‐in mice
The	 zQ175	 knock‐in	 line	 arose	 through	 a	 spontaneous	 expansion	 of	
the	CAG	repeat	 in	 line	Q140	(Heikkinen	et	al.,	2012;	Menalled	et	al.,	
2012)	 and	 both	 the	Q140	 and	 zQ175	 lines	 retained	 a	 neomycin	 re-
sistance	gene	cassette	 located	1.3	kb	upstream	of	 the	ATG.	 In	order	
to	test	whether	this	might	affect	the	expression	of	Htt,	or	the	level	of	
incomplete	splicing,	we	utilized	zQ175	mice,	from	the	CHDI	Foundation	
colony	 at	 the	Jackson	 Laboratories	 (Bar	Harbor,	Maine)	 in	which	 the	
neomycin	 cassette	had	been	 removed.	Heterozygous	 zQ175	 females	
(Jax	Stock#	370476)	had	been	crossed	to	homozygous	male	C57BL/6‐
Tg(Zp3‐cre)93Knw/J	(JAX	Stock#	003651)	in	which	Cre	was	expressed	
under	the	control	of	the	zona	pellucida	(Zp3)	promoter	(de	Vries	et	al.,	
2000),	which	drives	expression	exclusively	 in	growing	oocytes	before	
completion	of	the	first	meiotic	division.	The	resultant	zQ175DN	(delta	
neo)	 colony,	 on	 a	 C57BL/6J	 background	 (JAX	 Stock#	 000664)	 was	
established.	zQ175,	zQ175DN,	and	WT	mice	were	transferred	to	the	
Bates	colony	in	London	where	they	were	euthanized	at	2	months	of	age,	
brain	regions	were	snap	frozen	in	liquid	nitrogen	and	stored	at	−80°C.
2.2 | Cohorts of mice used for behavioral testing
The	numbers	of	animals	used	was	based	on	previous	experiments	
showing	 robust	 behavioral	 deficits	 have	 in	 homozygous	 Q140	
mice	on	a	mixed	strain	background	from	as	early	as	1	month	of	age	
(Dorner	et	al.,	2007;	Hickey	et	al.,	2008;	Menalled	et	al.,	2003;	Rising	
et	al.,	2011).
2.2.1 | Cohorts of mice used for the open field,  
Y‐maze, and pole task (1–6 months of age)
All	Q140,	HdhQ150,	and	their	WT	littermates	were	tested	on	the	pole	
task	(at	4	months	of	age).	A	subset	of	these	mice	was	used	at	1,	4,	and	
6	months	for	open	field	testing;	not	all	mice	that	underwent	pole	task	
testing	were	used	 for	open	field	because	genotypes	were	not	avail-
able	for	some	mice	at	1	month	of	age.	The	Y‐maze	was	introduced	as	
a	behavioral	test	part	way	through	the	study,	therefore	only	a	subset	
of	mice	that	were	enrolled	later	in	the	study	was	used	in	this	test.	The	
final	group	sizes	for	each	test	were	as	detailed	below.	WT	=	wild	type,	
Mut	=	mutant.	For open field:	Q140	WT	(n = 10; male n	=	3,	 female	
n	 =	7),	Q140	Mut	 (n = 9; male n	 =	4,	 female	n	 =	5),	HdhQ150	WT	
(n = 20; male n	 =	10,	 female	n	 =	10),	HdhQ150	Mut	 (n = 20; male 
n	=	12,	female	n	=	8).	For Y‐maze testing:	Q140	WT	(n = 7; male n	=	3,	
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female	n	=	4),	Q140	Mut	(n = 5; male n	=	2,	female	n	=	3),	HdhQ150	
WT	(n = 14; male n	=	7,	female	n	=	7),	HdhQ150	Mut	(n = 10; male 
n	=	6,	female	n	=	4).	For the pole task:	Q140	WT	(n = 10; male n	=	6,	
female	n	=	4),	Q140	Mut	(n = 9; male n	=	4,	female	n	=	5),	HdhQ150	
WT	(n = 29; male n	=	13,	female	n	=	16),	HdhQ150	Mut	(n = 24; male 
n	=	15,	female	n	=	9).	For	all	tests,	the	proportion	of	males	and	females	
did	not	significantly	differ	between	groups.	Fisher’s	exact	tests:	open	
field,	Q140	WT	v.	Q140	Mut	p	=	0.7512,	HdhQ150	WT	v.	HdhQ150	
Mut,	p	=	0.6499;	Y‐maze,	Q140	WT	v.	Q140	Mut	p	=	1.000,	HdhQ150	
WT	v.	HdhQ150	Mut,	p	=	0.6968;	pole	task,	Q140	WT	v.	Q140	Mut	
p	=	0.6563,	HdhQ150	WT	v.	HdhQ150	Mut,	p = 0.2712.
2.2.2 | Cohorts of mice used for the running wheel 
test at 6 months of age
A	separate	cohort	of	6	month	old	Q140,	HdhQ150,	and	WT	male	mice	
was	used	for	running	wheel	analysis.	Only	male	mice	were	used	because	
running	wheel	performance	is	affected	by	gender	and	the	estrous	cycle	
(Hickey	et	al.,	2008).	Group	sizes	were	as	 follows:	Q140	WT	 (n	=	6),	
Q140	Mut	(n	=	6),	HdhQ150	WT	(n	=	14),	and	HdhQ150	Mut	(n	=	10).	
Two	additional	Q140	WT	mice	were	included	in	running	wheel	testing,	
but	equipment	failed	to	detect	wheel	rotations	for	the	duration	of	test-
ing	for	these	two	mice.	At	the	conclusion	of	the	2	weeks	of	testing,	fresh	
frozen	brain	 tissue	was	collected	 from	all	mice	 that	were	 included	 in	
running	wheel	testing	at	6.5	months	of	age	for	RNA	analysis	(see	below).
2.3 | Behavioral testing
WT	and	homozygous	Q140	and	HdhQ150	mice	used	for	behavioral	
testing	were	habituated	 to	housing	 rooms	 adjacent	 to	our	 labora-
tory’s	behavioral	facility	for	1	week	prior	to	the	tests	commencing.	
Mice	were	housed	with	littermates	(up	to	4	per	cage)	in	reverse	light–
dark	cycle	conditions	(10	a.m.	to	10	p.m.).	All	tests	were	performed	
and	analyzed	by	an	experimenter	blind	to	genotype.
2.3.1 | Open field (1, 4 and 6 months of age)
Behavior	in	an	open	field	apparatus	(Tru	Scan,	Colbourn,	Allentown	
PA)	 was	 conducted	 under	 red	 lighting	 starting	 in	 the	 dark	 phase	
1	hr	after	lights	off	and	finishing	at	the	end	of	the	fourth	hour	after	
lights	off.	The	open	field	apparatus	consists	of	four	clear	plexiglass	
walls	(26.5	by	37.5	cm)	that	form	an	enclosure	with	two	rows	of	16	
infrared	 photocell	 beams	 to	 measure	 total	 horizontal	 locomotor	
activity.	Mice	were	placed	 into	the	open	field	and	activity	was	re-
corded	for	15	min.	The	apparatus	was	cleaned	using	Conflikt	(Decon	
Laboratories,	King	of	Prussia,	PA)	to	remove	odors	between	trials.
2.3.2 | Spontaneous alternation in the Y‐maze 
(3 months of age)
The	Y‐maze	was	used	to	test	spatial	working	memory	(Magen	et	al.,	
2012).	The	apparatus	was	a	three‐arm	horizontal	maze	 in	which	the	
arms	are	 symmetrically	disposed	at	120°	 angles	 to	each	other.	Two	
arms	(B	and	C)	were	15	cm	in	length	and	one	arm	(A)	was	20	cm	long.	
All	arms	were	5	cm	in	width	and	the	walls	were	12	cm	high.	The	maze	
was	made	out	of	opaque	white	plastic	boards	and	attached	to	a	square	
plastic	floor	27	cm	×	27	cm.	Mice	were	habituated	to	the	room	for	1	
hr	prior	to	the	test,	in	the	dark	phase.	The	maze	was	placed	in	a	red	
light	 illuminated	room.	Mice	were	initially	placed	in	the	 long	arm	(A)	
with	their	head	facing	the	maze	arms	(toward	the	point	at	which	arms	
meet).	The	animals	were	given	7	min	to	explore	the	maze,	while	a	tri-
pod	mounted	video	camera	recorded	arm	entries.	The	experimenter	
could	 not	 be	 seen	 by	 the	 animal	 during	 this	 time.	After	 7	min,	 the	
animal	was	 removed	 from	the	maze	and	 returned	 to	 its	home	cage.	
The	maze	was	thoroughly	cleaned	with	70%	of	ethanol	and	dried	after	
each	trial.	Alternation	in	the	Y‐maze	was	defined	as	consecutive	entry	
into	all	three	arms	(e.g.,	ABC,	CAB,	or	BCA,	but	not	BAB).	Behavior	was	
video‐recorded	and	alternations	were	counted	for	all	of	the	overlap-
ping	sequences	of	three	consecutive	entries	by	an	investigator	blind	
to	the	experimental	groups.	The	fraction	of	alternations	is	defined	as	
follows:	[(number	of	alternations)/(total	number	of	arm	entries−2)].
2.3.3 | Pole task (4 months of age)
Mice	were	examined	at	4	months	of	age	for	motor	performance	on	a	
vertical	pole	(1	cm	in	diameter,	60	cm	high)	as	described	previously	
(Hickey	et	al.,	2008).	In	this	test,	mice	were	placed	at	the	top	of	a	ver-
tical	pole	facing	upwards,	they	need	to	turn	to	face	downwards	and	
descend	the	pole.	Mice	were	habituated	to	the	task	in	two	trials	per	
day	for	2	days.	On	the	test	day	(day	3)	three	measures	were	taken	
over	five	trials	per	mouse:	the	total	time	taken	to	turn	and	descend,	
the	time	taken	to	turn	and	the	time	taken	to	descend	after	turning.
2.3.4 | Running wheel (6–6.5 months of age)
Mice	were	placed	individually	in	cages	equipped	with	a	running	wheel	
(23	cm	diameter,	Mini	Mitter	Company	 Inc.,	Bend,	OR).	Each	wheel	
rotation	was	 recorded	 in	 3‐min	 bins	 by	VitalView	 Data	Acquisition	
Software	V	4.0	(Mini	Mitter	Company	Inc.).	Running	wheel	cages	were	
housed	in	cabinets	(eight	cages/cabinet)	to	minimize	light	and	sound	
disturbance	(lights	off	10	a.m.,	lights	on	10	a.m.,	synchronized	with	the	
lights	in	the	housing	room).	Cabinets	were	equipped	with	fans	to	allow	
air	circulation.	Running	activity	was	recorded	continuously	for	14	days.	
After	7	days	mice	were	removed	from	the	cages	during	the	light	phase,	
weighed	and	their	food,	water	and	bedding	changed.	Wheel	running	
activity	during	light	and	dark	phases	was	calculated	using	ActiView	V	
1.2	(Mini	Mitter	Company	Inc.).	The	level	of	activity	during	each	dark	
phase	(“night”)	was	calculated	and	used	to	generate	the	mean	number	
of	rotations	per	3	min	for	each	night.
2.4 | Antibodies
The	 antibodies	 that	 were	 used	 for	 immunohistochemistry,	 immu-
noprecipitation	 and	 western	 blotting	 are	 summarized	 in	 Table	 1.	 
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3B5H10	 (RRID:AB_532270)	 is	 a	 monoclonal	 antibody	 that	 was	
raised	against	an	N‐terminal	171	amino	acid	fragment	of	HTT	with	
65Q	 and	 detects	 a	 polyQ	 tract	 (Peters‐Libeu	 et	 al.,	 2005).	 MW1	
(RRID:AB_528290)	and	MW8	(RRID:AB_528297)	are	a	monoclonal	
antibodies	that	were	raised	against	soluble	and	aggregated	versions	
of	exon	1	HTT	respectively	(Ko,	Ou,	&	Patterson,	2001).	MW1	and	
3B5H10	 recognize	 an	 expanded	 polyQ	 tract	 and	MW8	 acts	 as	 a	
neoepitope	antibody	on	western	blots	that	detects	the	AEEPLHRP	
peptide	at	the	C‐terminus	of	exon	1	HTT	Landles	et	al.	(2010).	These	
three	 antibodies	 were	 extensively	 characterized	 in	 Landles	 et	 al.	
(2010),	and	the	results	 in	this	paper	are	consistent	with	the	immu-
nodetection	of	HTT.
2.5 | HTT immunohistochemistry
Male	homozygous	Q140	and	HdhQ150	mice	(n	=	3/genotype)	at	4.5	
and	 12–13	months	 of	 age	were	 perfused	 transcardially	with	 0.01M	
of	phosphate	buffered	 saline	pH	7.2	 (PBS),	 followed	by	4%	of	para-
formaldehyde	(PFA),	and	0.5%	glutaraldehyde	in	PBS.	The	brains	were	 
removed,	post‐fixed	in	4%	of	paraformaldehyde	in	0.1M	PBS	for	6	hr	at	
4°C,	cryoprotected	in	30%	of	sucrose	for	72	hr,	cut	into	35‐µm‐thick	
sagittal	sections	on	a	Leica	CM	1800	cryostat	(Deerfield,	IL)	and	stored	
at	−20°	in	a	glycerol‐based	cryoprotectant	solution.	Sections	were	pro-
cessed	for	immunostaining	with	MW8	(Table	1).	After	washes	in	0.01M	
PBS,	the	sections	were	treated	with	H2O2	(1%)	in	PBS	containing	0.5%	
of	Triton	X‐100	 for	20	min	 to	block	endogenous	peroxidase	activity.	
Nonspecific	sites	were	blocked	by	incubating	the	sections	for	30	min	at	
room	temperature	in	PBS	containing	3%	of	bovine	serum	albumin	(BSA)	
and	2%	of	normal	goat	serum	(NGS).	The	sections	were	incubated	with	
MW8	1:1,000	in	PBS	containing	3%	of	BSA,	2%	of	NGS,	and	0.2%	of	
Triton	X‐100	(incubation	buffer)	for	24	hr	at	room	temperature.	After	
rinses	 in	PBS,	 the	 sections	were	 incubated	 in	biotinylated	goat	 anti‐ 
rabbit	antibody	(1:200)	(Vector	ABC	Elite,	Burlingame,	CA)	in	the	incu-
bation	buffer	for	2	hr	at	room	temperature.	After	several	rinses	in	PBS,	
the	sections	were	incubated	for	2	hr	in	avidin‐biotin	complex	(Vector	
ABC	Elite)	in	PBS	containing	0.2%	Triton	X‐100.	Immunoreactivity	was	
visualized	by	 incubation	 in	0.03%	3‐3′‐diaminobenzidine	 tetrahydro-
chloride	(Sigma,	St.	Louis,	MO)	and	0.0006%	H2O2	in	0.05	M	Tris	buffer,	
pH	7.6.	After	rinses	in	cold	Tris	buffer,	the	sections	were	dehydrated,	
defatted	 in	xylene,	and	mounted	with	Eukitt	 (Calibrated	 Instruments,	
Hawthorne,	 NY).	 Images	 of	 HTT	 staining	 were	 captured	 using	 an	
Olympus	microscope	connected	to	a	PC	with	SPOT	imaging	acquisition	
software.
2.6 | Immunoprecipitation and western blotting
Immunoprecipitation	with	3B5H10	and	mouse	IgG	(control)	followed	
by	western	blotting	with	MW1	and	MW8	were	performed	as	previ-
ously	described	(Landles	et	al.,	2010).
2.7 | Quantitative real‐time PCR analysis of selected 
striatal transcripts
At	the	conclusion	of	running	wheel	testing,	mice	were	euthanized	
by	cervical	dislocation	and	fresh	striatal	and	cortical	tissue	was	dis-
sected	using	a	 coronal	brain	matrix	 for	mice	with	1	mm	divisions	
(Stoelting	 Co.,	 Wood	 Dale,	 IL).	 Dissected	 tissue	 was	 snap‐fro-
zen	 in	 liquid	nitrogen	 and	 stored	 at	 −80º	C.	 Total	RNA	was	puri-
fied	 from	 fresh‐frozen	 brain	 tissue	 using	Qiagen	 RNeasy	mini	 kit	
(Qiagen)	according	to	the	manufacturers	recommendations.	During	
the	RNA	extraction	procedure,	on‐column	DNase	I	treatment	was	
performed	 to	 remove	 contaminating	 genomic	 DNA	 (RNase‐Free	
DNase	Set,	Qiagen).	RNA	was	stored	at	−80°C.	RNA	integrity	was	
confirmed	 using	 a	 BioAnalyzer	 (Agilent	 RNA	 6000	 Nano	 Assay,	
UCLA	Genotyping	and	Sequencing	Core).	For	cDNA	synthesis	with	
random	 hexamer	 primers,	 a	 High‐Capacity	 cDNA	 reverse	 tran-
scription	(RT)	kit	(Applied	Biosystems)	was	used.	cDNA	was	stored	
at	−20°C.	The	cDNA	was	 then	analyzed	by	quantitative	 real	 time	
PCR	 (qPCR)	using	 an	Applied	Biosystems	7900HT	Real	 time	PCR	
machine	(UCLA	Genotyping	and	Sequencing	Core).	PCR	reactions	
were	 performed	 using	 TaqMan	 gene	 expression	 assays	 (Applied	
Biosystems)	using	inventoried	primer‐probe	sets,	with	FAM	labeled	
probes.	Assay	identification	numbers	of	Applied	Biosystems	inven-
toried	primer‐probe	set	TaqMan	assays	of	striatal	transcripts	were:	
dopamine‐	 and	 cAMP‐regulated	 phosphoprotein	 32	 (Darpp32),	
Mm00454892_m1;	dopamine	receptor	D1	(Drd1a),	Mm01353211_
m1;	 dopamine	 receptor	 D2	 (Drd2),	 Mm00438545_m1;	 cannabi-
noid	 receptor	1(Cnr1),	Mm01212171_s1;	 preproenkephalin	 (Penk),	
Mm01212875_m1;	 high‐affinity	 glutamate	 transporter	 1	 (Glt1),	
Mm00441457_m1;	substance	P	receptor	(Tac1),	Mm00436892_m1.	
Identification	numbers	of	Applied	Biosystems	 inventoried	primer‐
probe	 set	 TaqMan	 assays	 of	 striatal	 and	 cortical	 reference	 genes	
were:	 ATP	 synthase,	H	 +	 transporting	mitochondrial	 F1	 complex,	
beta	 subunit	 (Atp5b),	 Mm00443967_g1;	 eukaryotic	 translation	
initiation	 factor	 4A2	 (Eif4a2),	 Mm00834357_g1;	 peptidylprolyl	
isomerase	A	(Ppia),	Mm02342429_g1.	For	each	gene,	RT	+	samples	
from	 each	 animal	 and	 no‐template	 controls	 samples	 were	 run	 in	
TA B L E  1  Summary	of	the	antibodies
Name Epitope Species Concentration Source
MW1 PolyQ Mouse	monoclonal WB	(1:1,000) CHDI	Foundation
MW8 AEEPLHRP Mouse	monoclonal WB	(1:1,000) CHDI	Foundation
IHC	(1:1,000)
3B5H10 PolyQ Mouse	monoclonal IP	2	µg Sigma	P1874
Abbreviations:	IHC,	immunohistochemistry;	IP,	immunoprecipitation;	WB,	western	blotting.
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triplicate	 and	RT‐samples	 run	 in	parallel.	 The	PCR	cycling	param-
eters	were	50°C	for	2	min,	95°C	for	10	min	(1	cycle);	95°C	for	15	s,	
60°C	for	1	min	(40	cycles).	Relative	expression	of	genes	of	interest	
were	determined	by	normalizing	to	the	geometric	mean	of	the	two	
most	stable	reference	genes	identified	using	the	geNorm	applet	for	
Microsoft	Excel	(reference	genes	are	Atp5b,	Ppia and Eif4a2),	as	pre-
viously	described	(Vandesompele	et	al.,	2002).
2.8 | Analysis of Htt transcripts by quantitative real‐
time PCR
Fresh	 striatal,	 cortical,	 and	 cerebellar	 tissue	 was	 dissected	 from	
mice	at	2	months	of	age,	snap‐frozen	 in	 liquid	nitrogen	and	stored	
at	 −80ºC.	 Tissue	 was	 homogenized	 in	 Qiazol	 buffer	 (Qiagen)	 
before	total	RNA	isolation	using	the	QiaGen	RNeasy	mini	kit	(Qiagen)	
and	RNA	was	quantified	using	a	Nanodrop	1000.	RNA	was	reverse	
transcribed	 using	 MMLV‐RT	 (Invitrogen)	 and	 oligo‐dT	 primers	
(Invitrogen)	and	cDNA	was	stored	at	−20°C.	qPCR	was	performed	
using	 SsoFast	 Probes	 Supermix	 (Bio‐Rad)	 with	 a	 corresponding	
cycler	 program	 using	 a	 CFX	 96	 qPCR	 system	 (Bio‐Rad).	 Primer‐
probe	 set	 gene	 expression	 assays	 for	 the	Htt	 intron	 1	 sequences	
were	 347F‐431R‐371P	 and	 for	 spliced	 Htt	 were	 ‐19F‐ex2R‐ex2P	
as	detailed	 in	Table	2.	Housekeeping	 reference	genes	were	Atp5b,	
Eif4a2,	 and	Ubc	 (striatum	and	cerebellum)	and	Atp5b,	Eif4a2,	Canx,	
and Rpl13a	(cortex)	from	Primer	Design	(Benn,	Fox,	&	Bates,	2008).	
The	 level	of	 intronic	 sequences	was	determined	by	normalizing	 to	
housekeeping	genes.	The	relative	levels	of	the	spliced	transcript	was	 
determined	by	the	2−ΔΔCt	method	(Benn	et	al.,	2008).
2.9 | Statistical analysis
A	 critical	 value	 of	 p	 <	 0.05	 was	 used	 for	 all	 statistical	 analysis.	
Grubb’s	test	for	outliers	was	performed	on	data	from	each	treat-
ment	group	and	 if	 a	 significant	outlier	was	 identified	 in	a	group,	
it	 was	 removed	 before	 comparisons	 between	 groups	 were	 per-
formed.	 SigmaPlot	 v12	 (Systat)	 or	 SPSS	 (v22)	 was	 used	 for	 all	
statistical	 analysis	 using	 one‐way	 ANOVA,	 two‐way	 ANOVA,	
or	 repeated‐measures	 two‐way	 ANOVA,	 as	 appropriate,	 with	
Bonferroni	or	Fisher’s	 LSD	post	hoc	 tests,	 as	 indicated.	Planned	
comparison	 Student’s	 t	 tests	 were	 also	 used	 where	 indicated.	
Graphs	were	prepared	using	GraphPad	Prism.
3  | RESULTS
To	evaluate	whether	phenotypes	develop	at	different	 rates	 in	 the	
Q140	 and	HdhQ150	 KI	 mice,	 we	 began	 by	 standardizing	 the	 ge-
netic	 background.	Q140	 and	HdhQ150	mice	were	 backcrossed	 to	
C57BL/6J	for	10	successive	generations	to	generate	99.9%	geneti-
cally	pure	congenic	lines	that	were	then	bred	to	homozygosity.	CAG	
repeat	sizes	were	relatively	comparable	between	the	lines	but	longer	
in	the	HdhQ150	(141.1	±	8.0	and	128.4	±	8.0)	compared	to	the	Q140	
(127.2	±	9.0	and	119.2	±	4.6)	mice.
3.1 | Q140 homozygotes, but not HdhQ150 
homozygotes are impaired in behavioral tasks before 
6 months of age
3.1.1 | Exploratory activity in the open field
Spontaneous	locomotion	of	homozygous	Q140	and	HdhQ150	mice,	
together	with	the	WT	littermates	from	both	lines	was	tested	in	an	
open	field	apparatus	at	1,	4	and	6	months	of	age	(Figure	1a).	At	all	
ages,	Q140	mice	showed	a	reduction	in	exploratory	behavior,	with	
a	shorter	total	movement	distance	during	15	min	in	the	open	field	
[two‐way	 repeated	 measures	 ANOVA,	 F(genotype)3,106	 =	 6.419,	
p = <0.001; F(age)2,106	 =	 28.581,	 p < 0.001; F(age	 ×	 geno-
type)6,106	=	0.251,	p	=	0.958.	Fisher’s	LSD	post	hoc	comparisons	
at	each	age:	1	month	Q140	MUT	v	WT,	p	=	0.001;	4	month	Q140	
MUT	v	WT,	p	=	0.038;	6	month	Q140	MUT	v	WT,	p	=	0.026].	 In	
contrast,	HdhQ150	mice	showed	normal	exploration	 in	the	open	
field	at	all	of	these	ages	[Fisher’s	LSD	post	hoc	comparisons	at	each	
age:	1	month	HdhQ150	MUT	v	WT,	p	=	0.923;	4	month	HdhQ150	
MUT	v	WT,	p	=	0.842;	6	month	HdhQ150	MUT	v	WT,	p	=	0.693].
3.1.2 | Spontaneous alternation in a Y‐maze
Spatial	working	memory	was	tested	by	spontaneous	alternation	in	a	
Y‐maze	in	3	month	old	mice	(Figure	1b).	Q140	mice	showed	a	reduced	
spontaneous	 alternation	 compared	 to	 WT	 littermates	 [two‐tailed	
Student’s	t	test,	p	=	0.029],	whereas	the	performance	of	HdhQ150	
mice	was	not	significantly	different	from	their	WT	counterparts	at	
the	same	age	[two‐tailed	Student’s	t	test,	p	=	0.197].	Therefore,	spa-
tial	working	memory	becomes	impaired	earlier	in	Q140	mice.
TA B L E  2  QPCR	assays	used	to	determine	comparative	levels	of	Htt	transcripts
Assay Primer/Probe Sequence
Intron	1:	347F‐431R‐371P Forward 5′‐TCCTCATCAGGCCTAAGAGCTGG‐3′
Reverse 5′‐GAGACCTCCTAAAAGCATTATGTCATC‐3′
Probe 5′‐AGTGCAGGACAGCGTGAGAGATGTG‐3′
Exon	1—Exon	2‐19F‐ex2R‐ex2P Forward 5′‐AGGAACCGCTGCACCGA‐3′
Reverse 5′‐CTGAGAGACTGTGCCACAATGTT‐3′
Probe 5′‐AGAAAGACCGTGTGAATCATTGTCTAACAATATGTGA‐3′
Note: The	primers	and	probes	for	the	TaqMan	qPCR	assay	are	listed.
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3.1.3 | Descent from a vertical pole
Mice	were	placed	at	the	top	of	a	vertical	pole	in	a	head‐up	orienta-
tion.	At	4	months	of	age,	Q140	mice	showed	an	impairment	both	in	
the	time	to	turn	to	a	head‐down	position,	as	well	as	in	the	time	taken	
to	descend	the	pole,	as	compared	to	their	WT	littermates	[One‐way	
ANOVA:	time	to	turn,	F(genotype)3,64	=	5.254,	p	=	0.003;	Bonferroni	
post	hoc	comparisons:	Q140	MUT	v	WT,	p	=	0.031;	time	to	descend,	
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F(genotype)3,64	=	3.917,	p	=	0.012;	Bonferroni	post	hoc	comparisons:	
Q140	MUT	v	WT,	p	=	0.022].	In	contrast,	HdhQ150	mice	were	not	
impaired	at	this	task	[Bonferroni	post	hoc	comparisons:	time	to	turn,	
HdhQ150	MUT	v	WT,	p	=	1.000;	time	to	descend,	HdhQ150	MUT	v	
WT,	p	=	1.000]	(Figure	1c,d).
3.1.4 | Performance in a running wheel
Running	wheel	 performance	 in	 a	 separate	 cohort	 of	male	Q140	mice	
and HdhQ150	mice,	as	compared	to	their	WT	littermates,	was	tested	at	
6	months	of	age.	Q140	mice	showed	a	reduced	mean	nightly	running	wheel	
performance	compared	to	WT	littermates.	Two‐way	repeated	measures	
ANOVA:	 F(genotype)3,372	 =	 2.035,	 p	 =	 0.129,	 F(night)12,372	 =	 23.795,	
p	 <	 0.001,	F(genotype	 ×	 night)36,372	 =	 0.986,	p	 =	 0.496.	 Fisher’s	 LSD	
post	hoc	comparisons	showed	significantly	reduced	running	on	nights	7	
(p	=	0.048),	8	(p	=	0.032),	9	(p	=	0.007),	10	(p	=	0.013),	12	(p	=	0.045)	and	
13	(p	=	0.031).	There	was	no	difference	detected	by	Fisher’s	LSD	post	hoc	
comparisons	for	the	HdhQ150	mice	(Figure	1e,f).
In	 summary,	 homozygous	Q140	have	decreased	 locomotion	 in	
the	 open	 field	 at	 1–6	months,	 decreased	 spontaneous	 alternation	
in	the	Y‐maze	at	3	months,	impairment	in	the	pole	task	at	4	months	
and	decreased	running	wheel	performance	at	6	months.	We	did	not	
detect	any	deficits	in	the	homozygous	HdhQ150	mice	in	these	tests	
at	the	same	ages.
3.2 | HTT immunostaining detects aggregates in the 
striatum earlier in Q140 than in HdhQ150 mice
The	choice	of	antibody	for	use	in	immunohistochemical	experiments	
to	 investigate	 the	 timing	 of	 HTT	 deposition	 in	 the	 brains	 of	 these	
two	 mouse	 models	 had	 to	 be	 considered	 carefully.	 The	 Q140	 and	
HdhQ150	mice	express	human	and	mouse	exon	1	HTT,	respectively,	
and	many	 antibodies	 raised	 against	 exon	 1	 HTT	 sequences,	 detect	
human,	and	mouse	HTT	differently.	For	example,	monoclonal	EM48	
does	not	detect	mouse	HTT	(Wang	et	al.,	2008)	and	therefore	poly-
clonal	EM48	may	detect	human	and	mouse	HTT	with	different	affini-
ties.	Similarly,	the	polyclonal	S830	(Sathasivam	et	al.,	2001)	most	likely	
recognizes	 the	human	proline	rich	sequence	and	also	should	not	be	
used.	In	contrast,	the	epitope	for	MW8	is	present	in	both	mouse	lines	
(Ko	et	al.,	2001),	this	antibody	readily	detects	aggregated	HTT	(Ko	et	
al.,	2001;	Landles	et	al.,	2010),	and	we	have	no	evidence	to	indicate	
that	this	antibody	has	a	different	affinity	for	human	and	mouse	HTT.
Striatal	sections	from	homozygous	Q140	and	HdhQ150	mice	aged	
4.5	 and	12–13	months	 and	 their	WT	 controls	were	 immunoprobed	
with	MW8.	No	specific	staining	was	observed	in	the	brains	of	the	WT	
mice	at	7	and	12	months,	respectively	(Figure	2a,d).	At	4.5	months	of	
age,	a	diffusely	distributed	HTT	species	had	accumulated	in	neuronal	
nuclei	in	the	striatum	of	Q140	mice	and	small	nuclear	inclusions	could	
be	observed	in	some	sections	(Figure	2b).	In	contrast,	this	nuclear	ac-
cumulation	of	HTT	was	barely	detectable	on	sections	from	HdhQ150	
animals	 (Figure	2e).	At	12–13	months	of	age,	 the	nuclear	 inclusions	
and	 neuropil	 aggregates	 were	 readily	 observed	 in	 both	 Q140	 and	
HdhQ150	striata	(Figure	2c,f),	and	the	Q140	mice	appeared	to	have	
smaller	nuclear	inclusions	and	a	greater	number	of	neuropil	aggregates.
3.3 | Homozygous Q140 and HdhQ150 mice have 
similar levels of transcriptional dysregulation in the 
striatum at 6.5 months of age
Transcriptional	 dysregulation	 is	 a	well‐defined	molecular	HD	phe-
notype	that	has	been	extensively	studied	in	HD	mouse	models	and	
in post mortem	brains	(Hodges	et	al.,	2006;	Langfelder	et	al.,	2016),	
for	which	distinct	changes	in	the	expression	pattern	of	striatal	genes	
has	been	documented.	To	determine	whether	differences	between	
Q140	 and	HdhQ150	mice	 could	 be	 observed	 at	 the	 level	 of	 tran-
scriptional	changes,	we	measured	the	levels	of	selected	striatal	tran-
scripts	 by	 real	 time	 quantitative	 PCR	 (qPCR)	 in	male	 homozygous	
Q140	 and	HdhQ150	mice	 at	 6.5	months	 of	 age.	 Brains	 had	 been	
F I G U R E  1  Behavioral	characterization	of	homozygous	C57BL/6J	congenic	Q140	and	HdhQ150	mice.	(a)	Total	movement	in	open	field	
for	homozygous	Q140	and	HdhQ150	mice	and	WT	littermates.	Graph	shows	mean	+	SEM	distance	(cm)	during	15	min	in	the	open	field	
apparatus	at	1,	4,	and	6	months	of	age.	Two‐way	repeated	measures	ANOVA	with	Fisher’s	LSD	post	hoc	tests	at	each	age.	Group	sizes:	Q140	
mutant	(n	=	9),	Q140	WT	littermates	(n	=	10),	HdhQ150	mutant	(n	=	20),	HdhQ150	WT	littermates	(n	=	20).	(b)	Spontaneous	alternation	in	
Y‐maze	of	homozygous	Q140	and	HdhQ150	mice	and	WT	littermates	at	3	months	of	age.	Graph	shows	mean	+	SEM	fraction	of	alternations	
calculated	as	number	of	sequential	entries	into	all	three	arms	of	the	Y‐maze,	divided	by	the	total	number	of	arm	visits	minus	2.	Two‐tailed	
Student’s	t	test.	Group	sizes:	Q140	mutant	(n	=	5),	Q140	WT	littermates	(n	=	7),	HdhQ150	mutant	(n	=	10),	HdhQ150	WT	littermates	(n	=	14).	
(c	and	d)	Time	to	turn	and	descend	a	vertical	pole	for	homozygous	Q140	and	HdhQ150	mice	and	their	WT	littermates	at	4	months	of	age.	
Graphs	show	mean	+	SEM	time	(sec)	to	turn	(c)	and	descend	(d)	a	vertical	pole.	One‐way	ANOVA	with	Bonferroni	post	hoc	tests.	Group	
sizes:	Q140	mutant	(n	=	8),	Q140	WT	littermates	(n	=	9),	HdhQ150	mutant	(n	=	23),	HdhQ150	WT	littermates	(n	=	28).	(e	and	f)	Running	
wheel	performance	in	homozygous	Q140	and	HdhQ150	mice	and	their	WT	littermates	at	6	months	of	age.	Graphs	show	mean	+	SEM 
running	wheel	(RW)	rotations	per	3	min,	during	the	12‐hr	dark	phase	of	the	24‐hr	light	cycle	(night).	Graphs	show	performance	of	6	month	
old	male	mice:	(e)	Q140	mutant	mice	and	WT	littermates,	(f)	HdhQ150	mutant	mice	and	WT	littermates,	during	each	night	over	two	weeks	
housed	in	the	RW	apparatus.	Repeated	measures	two‐way	ANOVA	(comparing	all	four	genotype	groups;	graphs	show	knock‐in	mouse	
lines	separately	for	clarity).	Fisher’s	LSD	post	hoc	comparisons	showed	no	difference	in	running	wheel	activity	on	nights	1	(p	=	0.417),	2	
(p	=	0.051),	3	(p	=	0.089),	4	(p	=	0.371),	5	(p	=	0.190),	6	(p	=	0.100),	or	11	(p	=	0.071),	but	significantly	reduced	running	was	observed	on	nights	
7	(p	=	0.048),	8	(p	=	0.032),	9	(p	=	0.007),	10	(p	=	0.013),	12	(p	=	0.045),	and	13	(p	=	0.031),	There	was	no	difference	detected	by	Fisher’s	
LSD	post	hoc	comparisons	for	the	HdhQ150	mice	(nights	1	(p	=	0.450),	2	(p	=	0.151),	3	(p	=	0.163),	4	(p	=	0.701),	5	(p	=	0.419),	6	(p	=	0.993),	
7	(p	=	0.804),	8	(p	=	0.809),	9	(p	=	0.447),	10	(p	=	0.728),	11	(p	=	0.883),	12	(p	=	0.388),	and	13	(p	=	0.800).	Group	sizes:	Q140	mutant	(n	=	6),	
Q140	WT	littermates	(n	=	6),	HdhQ150	mutant	(n	=	10),	HdhQ150	WT	littermates	(n	=	14)
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harvested	from	these	mice	immediately	following	the	completion	of	
running	wheel	behavioral	testing	in	which	the	performance	of	Q140	
mice,	but	not	HdhQ150	mice,	was	impaired.
The	expression	 levels	of	 the	 striatal	 genes:	dopamine	 receptor	
D2	(Drd2),	preproenkephalin	(Penk1),	Darpp32,	and	cannabinoid	re-
ceptor	1	(Cnr1)	mRNAs	were	decreased	in	both	Q140	and	HdhQ150	
mice	 (Figure	 3a,b).	 This	 is	 consistent	 with	 our	 previous	 data	 for	
4.5	month	old	homozygous	Q140	mice	on	a	mixed	strain	background	
(Hickey,	 Franich,	 Medvedeva,	 &	 Chesselet,	 2011).	 Therefore,	 the	
Q140	and	HdhQ150	mice	have	similar	decreases	 in	the	expression	
levels	of	 these	 signature	 striatal	 genes	 at	6.5	months,	 despite	 the	
absence	of	motor	phenotypes	in	the	HdhQ150	model,	and	its	better	
performance	on	the	running	wheel	 task	 (which	might	be	expected	
to	increase	transcription	levels).	Given	that	this	transcriptional	dys-
regulation	precedes	the	onset	of	behavioral	deficits	in	the	HdhQ150	
mice,	the	transcriptional	repression	of	Drd2,	Penk1,	Darpp32,	or	Cnr1 
does	not	influence	the	onset	of	the	behavioral	phenotypes	that	we	
have	measured	in	these	knock‐in	lines.
3.4 | The incomplete splicing of Htt is greater in the 
Q140 than HdhQ150 mice
We	have	previously	shown	that	exon	1	of	HTT	does	not	always	splice	
to	exon	2	generating	a	small	exon	1—intron	1	polyadenylated	mRNA	
(Httexon1)	that	encodes	the	highly	pathogenic	exon	1	HTT	protein.	
Termination	 of	 this	mRNA	 occurs	 at	 cryptic	 polyadenylation	 sites	
located	at	680	and	1,145	bp	into	intron	1.	This	level	of	incomplete	
splicing	increases	with	increasing	CAG	repeat	length	and	occurs	in	all	
knock‐in	mouse	models	of	HD,	in	YAC128	mice,	and	in	HD	postmor-
tem	brains	and	fibroblast	cell	lines	(Neueder	et	al.,	2017;	Sathasivam	
et	al.,	2013).	Therefore,	we	set	out	to	determine	whether	levels	of	
incomplete	splicing,	and	consequently,	of	 the	exon	1	HTT	protein,	
might	 underlie	 the	 differences	 in	 the	 onset	 of	HD‐related	 pheno-
types	in	these	mouse	models.
We	measured	 the	 level	 of	 intron	 1	 sequences,	 using	 a	 qPCR	
assay	 that	 amplified	 sequences	 located	 in	 the	 5′	 region	 of	 Htt 
intron	 1,	 before	 the	 first	 cryptic	 polyadenylation	 site.	 RNA	was	
prepared	from	striatum,	cortex,	and	cerebellum	from	2	month	old	
homozygous	 Q140	 and	 HdhQ150	 mice,	 together	 with	 their	 re-
spective	WT	littermates.	We	detected	higher	levels	of	intron	1	se-
quences	in	Q140	brains	as	compared	to	HdhQ150	in	all	three	brain	
regions	(Figure	4a).	The	level	was	between	2.5‐	and	3‐fold	higher	
in	 the	 striatum,	 between	 1.5‐	 and	 2‐fold	 higher	 in	 the	 cortex,	
and	approximately	1.3‐fold	higher	 in	 the	cerebellum.	 Incomplete	
splicing	 would	 be	 expected	 to	 lead	 to	 lower	 levels	 of	 the	 cor-
rectly	spliced,	full‐length	mutant	Htt	mRNA.	In	order	to	determine	
whether	this	was	the	case,	we	used	a	qPCR	assay	that	spanned	the	
exon	1—exon	2	splice	junction.	The	level	of	the	spliced	mRNA	was	
statistically	 significantly	decreased	 in	 the	 striatum	and	cortex	 in	
HdhQ150	mice,	and	there	was	a	trend	toward	a	reduction	 in	the	
F I G U R E  2  Striatal	HTT	immunostaining	in	homozygous	Q140	and	HdhQ150	mice.	Sagittal	striatal	sections	from	(a)	WT	mice	aged	
7	months,	(b)	Q140	mice	aged	4.5	months	(c)	Q140	mice	aged	13	months,	(d)	WT	mice	aged	12	months,	(e)	HdhQ150	mice	aged	4.5	months	
and	(f))	HdhQ150	mice	aged	12	months	immunostained	with	MW8.	At	4.5	months	of	age,	Q140	mice	showed	stronger	diffuse	nuclear	
HTT	staining	compared	with	HdhQ150	mice.	At	12–13	months	of	age,	both	Q140	and	HdhQ150	mice	have	HTT	inclusions	and	neuropil	
aggregates.	However,	Q140	mice	show	more	neuropil	aggregates	in	the	striatum	than	HdhQ150	mice.	Scale	bar	=	20	μm,	applies	to	all	
images
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Q140	mice	in	both	of	these	brain	regions,	when	compared	to	their	
WT	littermates	(Figure	4b),
We	 used	 the	 3B5H10	 antibody	 to	 immunoprecipitate	 HTT	
from	the	brains	of	heterozygous	Q140	and	HdhQ150	mice	at	2	and	
12	months	of	age.	Heterozygous	mice	were	chosen	for	this	purpose	
because	 in	 homozygous	 mice,	 the	 difference	 in	 polyQ	 length	 on	
the	mutant	HTT	alleles	makes	 it	difficult	 to	 interpret	 the	patterns	
of	 N‐terminal	 fragments	 immunoprecipitated	 from	 their	 brains.	
The	 3B5H10	 antibody	 recognizes	 an	 expanded	 polyQ	 repeat	 and	
so	 does	 not	 immunoprecipitate	HTT	 from	WT	 tissues	 (Figure	 4c).	
In	 contrast,	 immunodetection	 with	MW1	 showed	 that	 full‐length	
HTT,	as	well	as	 the	characteristic	pattern	of	N‐terminal	 fragments	
(Landles	et	al.,	2010),	were	immunoprecipitated	from	both	Q140	and	
HdhQ150	brains.	Comparison	of	fragment	 intensities	 in	the	 immu-
noprecipitates	from	the	brains	of	both	mouse	models	at	2	months	
of	age,	did	not	demonstrate	any	obvious	differences	for	fragments	
F I G U R E  3  Expression	level	of	striatal	transcripts	in	homozygous	Q140	and	HdhQ150	mice	and	their	WT	littermates	at	6.5	months	
of	age.	Relative	levels	of	selected	striatal	transcripts	assessed	by	qPCR	in	6.5‐month–old‐male	(a)	homozygous	Q140	mice	(n	=	5–6)	
and	WT	littermates	(n	=	7–8)	and	(b)	homozygous	HdhQ150	mice	(n	=	8)	and	WT	littermates	(n	=	8).	One‐way	ANOVA	comparing	all	
four	genotypes	with	Fisher’s	LSD	post	hoc	tests,	mean	+	SEM: Drd2: F(genotype)3,25	=	3.990,	p = 0.019; Penk: F(genotype)3,25	=	5.917,	
p = 0.003; Darpp32: F(genotype)3,26	=	4.463,	p = 0.012; Cnr1: F(genotype)3,25	=	6.526,	p = 0.002; Drd1a: F(genotype)3,25	=	2.338,	
p	=	0.098;	Glt1: F(genotype)3,26	=	2.388,	p = 0.092; Tac1: F(genotype)3,26	=	0.519,	p	=	0.673.	#Planned	comparison	two‐tailed	Student’s	
t	tests.	Drd2	=	dopamine	receptor	D2,	Penk1	=	preproenkephalin,	Darpp32	=	dopamine‐	and	cAMP‐regulated	phosphoprotein	32,	
Cnr1	=	cannabinoid	receptor	1,	Glt1	=	glutamate	transporter,	Tac1	=	tachykinin	1	receptor	(Substance	P	receptor)
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running	at	~70	kDa	and	above.	However,	the	intensity	of	the	small-
est	fragment	that	had	migrated	to	the	bottom	of	the	gel	appeared	
stronger	 in	 the	 Q140	 than	 in	 the	HdhQ150	 lysates.	 The	 3B5H10	
immunoprecipitates	were	resolved	on	a	separate	gel,	and	this	time	
were	immunoprobed	with	MW8,	which,	on	western	blots,	acts	as	a	
neoepitope	antibody	for	the	C‐terminus	of	the	exon	1	HTT	protein	
(Landles	et	al.,	2010).	MW8	only	recognized	the	smallest	fragment,	
demonstrating	that	this	is	exon	1	HTT	and	that	its’	level	is	higher	in	
lysates	from	Q140	brains	as	compared	to	HdhQ150	in	2	month	old	
mice	 (Figure	 4c).	 The	 exon	 1	HTT	 protein	was	 not	 present	 in	 the	
12	month	Q140	or	HdhQ150	lysates,	as	by	this	age	it	has	been	re-
cruited	into	aggregates.
3.5 | The presence of a neomycin cassette in the 
Q140 line is unlikely to influence the levels of 
incomplete splicing
In	 engineering	 the	Q140	mice	 to	 express	 a	 chimeric	Htt	 gene	with	
human	exon	1	and	an	expanded	CAG	repeat,	a	neomycin	resistance	
gene	remained	located	1.3	kb	5′	to	the	ATG.	Although	this	neo	gene	
was	 transcribed	 in	 the	 opposite	 direction	 to	Htt,	 it	 is	 possible	 that	
its’	 presence	might	 influence	 the	 level	 of	 incomplete	 splicing	 in	 the	
Q140	mice.	A	spontaneous	CAG	repeat	expansion	 in	 the	Q140	 line	
has	 led	 to	 the	 knock‐in	mouse	 line	 now	 dubbed	 zQ175	 (Heikkinen	 
et	al.,	2012;	Menalled	et	al.,	2012),	from	which	the	neomycin	cassette	
F I G U R E  4  The	level	of	the	Httexon1	transcript	and	exon	1	HTT	protein	is	greater	in	Q140	than	HdhQ150	brains	at	2	months	of	age.	
(a)	Htt	intron	1	sequences	detected	by	qPCR	(347f‐431r)	in	the	striatum,	cortex	and	cerebellum	of	Q140	and	HdhQ150	mice,	and	their	
respective	WT	littermates	at	2	month	of	age.	The	level	of	the	Httexon1	transcript	was	greater	in	Q140	than	in	HdhQ150	mice	in	all	brain	
regions	Student’s	t	test	(two‐tailed)	±	SEM.	Intron	1	sequences	were	not	detected	in	WT	mice.	(b)	Full‐length	Htt	levels	as	detected	by	qPCR	
(‐19f‐ex2r)	in	the	striatum,	cortex,	and	cerebellum	of	Q140	and	HdhQ150	mice	as	compared	to	their	respective	WT	littermates	at	2	month	
of	age.	The	level	of	the	correctly	spliced	Htt	transcript	was	lower	in	the	HdhQ150	striatum	and	cortex	compared	to	WT	and	there	was	a	
trend	toward	a	reduction	in	the	Q140	mice	for	these	two	brain	regions	(one‐way	ANOVA	with	Bonferroni	post	hoc	tests)	mean	±	SEM.	(a,	b)	
Q140	mutant	(n	=	5),	Q140	WT	(n	=	7),	HdhQ150	mutant	(n	=	6),	HdhQ150	WT	(n	=	7).	Transcripts	were	normalized	to	the	geometric	mean	
of	the	housekeeping	genes:	Atp5b and Eif4a2.	(c)	Mutant	HTT	proteins	were	immunoprecipitated	with	the	3B5H10	antibody	using	Protein	
G	agarose	beads	(Invitrogen)	from	either	WT,	HdhQ150	or	Q140	brains	at	2	months	of	age,	and	western	blots	were	immunoprobed	with	
either	MW1	or	MW8.	MW1	detects	the	characteristic	pattern	of	N‐terminal	HTT	fragments	(Landles	et	al.,	2010)	and	MW8	shows	that	
the	smallest	fragment	is	the	exon	1	HTT	protein	(arrows).	The	level	of	exon	1	HTT	is	greater	in	Q140	than	in	HdhQ150	brains.	The	smaller	
fragments	migrate	at	different	rates	due	to	variation	in	the	length	of	the	polyQ	tract.	HTT	proteins	were	immunoprecipitated	from	HdhQ150	
and	Q140	brains	at	12	months	of	age.	The	soluble	exon	1	HTT	protein	is	no	longer	detectable	in	these	lysates,	because	it	has	been	recruited	
into	aggregates.	Immunoprecipitation	with	mouse	IgG	antibody	alone	served	as	a	negative	control
12  |     FRANICH et Al.
has	subsequently	been	removed	to	generate	the	zQ175DN	(delta	neo)	
line.	In	order	to	investigate	the	effect	of	the	neo	gene	on	exon	1	splic-
ing,	we	therefore	compared	the	level	of	incomplete	splicing	in	2	month	
old	 zQ175	mice,	with	 and	without	 the	 neomycin	 cassette.	The	 lev-
els	of	5′	 intron	1	sequence,	before	the	first	cryptic	polyA	site,	were	
measured	by	qPCR	in	the	striatum,	cortex,	and	cerebellum	(Figure	5a).	
There	 was	 no	 difference	 in	 the	 levels	 of	 these	 intronic	 sequences	 
between	the	zQ175	and	zQ175DN	mice	in	any	of	these	brain	regions.	
Therefore,	the	presence	of	the	neomycin	cassette	in	the	Q140	mice	
was	unlikely	 to	be	 responsible	 for	 the	 increased	 level	of	 incomplete	
splicing	when	compared	to	that	in	the	HdhQ150	line.	The	levels	of	the	
correctly	spliced	Htt	 transcripts	were	also	measured	by	qPCR.	Once	
again,	there	was	no	difference	in	the	levels	of	full‐length	Htt	between	
the	zQ175	and	zQ175DN	mice	in	any	of	the	three	brain	regions	tested	
(Figure	5b).
4  | DISCUSSION
Previous	 studies	 had	 suggested	 that	 the	onset	 of	 behavioral	 defi-
cits	in	Q140	mice	might	occur	much	earlier	than	in	HdhQ150	mice	
(Brooks	et	al.,	2012;	Dorner	et	al.,	2007;	Heng	et	al.,	2007;	Hickey	
et	al.,	2008;	Lerner,	Trejo	Martinez	Ldel,	Zhu,	Chesselet,	&	Hickey,	
2012;	 Lin	 et	 al.,	 2001;	Menalled	 et	 al.,	 2003;	 Rising	 et	 al.,	 2011;	
Simmons	 et	 al.,	 2009;	 Woodman	 et	 al.,	 2007).	 To	 systematically	
evaluate	 these	 potential	 differences,	 we	 standardized	 the	 genetic	
background	 by	 generating	 Q140	 and	 HdhQ150	 C57BL/6J	 con-
genic	lines,	bred	them	to	homozygosity	and	maintained	them	under	
identical	husbandry	conditions.	We	performed	carefully	controlled	
comparisons	of	behavioral	phenotypes,	and	confirmed	 that,	as	we	
had	previously	shown,	the	Q140	mice	exhibited	deficits	in	explora-
tory	behavior	in	the	open	field	at	1,	4,	and	6	months	of	age,	sponta-
neous	alternation	in	the	Y‐maze	at	3	months,	the	vertical	pole	test	
at	4	months	and	night	time	wheel	running	performance	at	6	months.	
However,	the	HdhQ150	mice	had	yet	to	develop	a	deficit	in	any	of	
these	tests	by	6	months	of	age.	Although	the	CAG	repeat	expansions	
in	these	two	lines	were	relatively	well‐matched,	they	were	slightly	
higher	 in	 the	Hdh150	mice,	 and	 so	 could	 not	 have	 accounted	 for	
these	differences.
The	deposition	of	aggregated	HTT	in	the	striatum	precedes	that	
in	most	other	brain	regions	in	both	the	Q140	(Menalled	et	al.,	2003)	
and HdhQ150	knock‐in	 lines	 (Woodman	et	al.,	2007).	Within	neu-
ronal	 nuclei,	 immunohistochemistry	 first	 reveals	 this	 as	 a	 diffuse	
staining	pattern	that	fills	the	entire	nucleus,	from	which	puncta	ap-
pear	and	then	coalesce	into	a	single	large	nuclear	inclusion	as	patho-
genesis	proceeds	 (Li	et	al.,	1999;	Menalled	et	al.,	2003).	We	know	
that	this	diffuse	staining	pattern	represents	an	aggregated	form	of	
HTT,	because	it	cannot	be	detected	by	immunohistochemistry	with	
antibodies	that	recognize	the	polyQ	tract,	as	this	epitope	is	buried	
in	the	aggregate	structure;	however,	pretreatment	with	formic	acid,	
breaks	open	the	cross‐β‐sheet	H‐bonding,	exposing	the	polyQ	epi-
tope	(Landles	et	al.,	2010).	In	order	to	determine	whether	the	depo-
sition	of	HTT	aggregates	in	the	striatum	occurs	at	different	ages	in	
Q140	 and	 HdhQ150	 mice,	 we	 performed	 immunohistochemistry	
with	MW8,	an	antibody	 for	which	 the	AEEPLHRP	epitope	 is	pres-
ent	in	both	mouse	and	human	HTT,	and	therefore,	in	both	of	these	
F I G U R E  5   Httexon1	and	full‐length	Htt	transcript	levels	are	comparable	in	2	month	old	zQ175	and	zQ175DN	brains.	(a)	Htt	intron	1	
sequences	detected	by	qPCR	(347f‐431r)	in	the	striatum,	cortex	and	cerebellum	of	heterozygous	zQ175,	heterozygous	zQ175DN	and	WT	
mice	at	2	month	of	age.	There	was	no	difference	in	the	level	of	the	Httexon1	transcript	between	zQ175	and	zQ175DN	mice	for	all	brain	
regions	Student’s	t	test	(two‐tailed)	mean	±	SEM.	Intron	1	sequences	were	not	detected	in	WT	mice.	(b)	Full‐length	Htt	levels	as	detected	
by	qPCR	(‐19f‐ex2r)	in	the	striatum,	cortex	and	cerebellum	of	zQ175,	zQ175DN	and	WT	mice	at	2	month	of	age.	There	was	no	statistical	
difference	between	the	groups	for	any	of	the	brain	regions	analyzed	(one‐way	ANOVA	with	Bonferroni	post	hoc	tests).	(a	and	b)	zQ175	
(n	=	12),	zQ175DN	(n	=	10),	WT	(n	=	8).	Transcripts	were	normalized	to	the	geometric	mean	of	the	housekeeping	genes:	Atp5b,	Eif4a2 and 
Ubc	(striatum	and	cerebellum),	or	Atp5b,	Canx and Rpl13a	(cortex)
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mouse	 lines.	At	4.5	months	of	age,	 immunostaining	with	MW8	re-
vealed	a	prominent	neuronal	nuclear	staining	pattern	that	was	barely	
detectable	 in	striatal	sections	 from	HdhQ150	mice,	 indicating	that	
the	aggregation	process	has	started	earlier	 in	the	Q140	striata.	To	
investigate	whether	transcriptional	dysregulation	might	also	initiate	
at	different	ages,	we	measured	the	levels	of	a	signature	set	of	striatal	
transcripts,	known	to	be	dysregulated	in	HD	mice,	at	6.5	months	of	
age.	We	found	that	these	transcripts	were	down‐regulated	in	both	
lines	to	comparable	extents,	indicating	that	they	could	not	contrib-
ute	the	behavioral	deficits	in	the	Q140	mice,	as	these	had	not	been	
detected	 in	 the	HdhQ150	 line.	 It	would	 be	 necessary	 to	measure	
these	 transcripts	 at	 an	 earlier	 age	 in	 order	 to	 determine	whether,	
as	with	aggregation,	 transcriptional	dysregulation	occurs	earlier	 in	
Q140	mice.
We	had	previously	shown	that	all	knock‐in	mouse	lines	express	
the	highly	pathogenic	exon	1	HTT	protein,	through	the	incomplete	
splicing	of	exon	1	Htt	to	exon	2	(Sathasivam	et	al.,	2013).	Therefore,	
the	earlier	onset	of	the	behavioral	phenotypes	in	the	Q140	line	might	
have	occurred	because	they	expressed	higher	levels	of	exon	1	HTT.	
To	investigate	this	possibility,	we	measured	the	levels	of	5’	intron	1	
Htt	sequences	in	the	striatum,	cortex	and	cerebellum	in	homozygous	
Q140	and	HdhQ150	mice	 at	 2	months	of	 age.	We	 found	 that	 the	
levels	of	the	Httexon1	mRNA	were	2–3‐fold	higher	in	the	striatum,	
1.5–2‐fold	higher	in	the	cortex	and	~1.3‐fold	higher	in	the	cerebellum	
in	CAG140	as	compared	to	HdhQ150	mice.	Immunoprecipitation	of	
mutant	HTT	from	whole	brain	lysates,	followed	by	western	blotting,	
indicated	that	the	Q140	mice	had	higher	 levels	of	the	exon	1	HTT	
protein,	as	would	be	predicted.	Consistent	with	 the	occurrence	of	
incomplete	Htt	splicing,	the	levels	of	spliced	Htt	were	decreased	in	
both	lines	when	compared	to	WT	levels.
The	strategy	by	which	 the	Q140	and	HdhQ150	knock‐in	 lines	
were	created	resulted	in	a	number	of	sequence	differences	in	the	5’	
region	of	the	modified	Htt	genes	(Figure	6).	In	the	HdhQ150	mice	an	
expanded	CAG	repeat	had	been	introduced	into	mouse	Htt	through	a	
double	homologous	recombination	replacement	event	that	resulted	
in	no	other	modifications	to	the	locus	(Lin	et	al.,	2001)	(Figure	6a).	
In	contrast,	the	Q140	mice	were	generated	by	replacing	an	XmnI—
KpnI	fragment	of	mouse	Htt	with	an	XmnI—Kpn	from	human	HTT 
containing	an	expanded	CAG	repeat	(Levine	et	al.,	1999;	Menalled	 
et	al.,	2003)	 (Figure	6b).	Therefore,	Q140	and	HdhQ150	mice	dif-
fer	 in	 the	 human	 and	 mouse	 exon	 1	 HTT	 amino	 acid	 sequences	
(Figure	6c),	and	the	Q140	mice	also	have	a	neomycin	gene	cassette	
5’	to	the	ATG	and	84	bp	of	mouse	intron	1	has	been	replaced	with	
10	bp	of	human	intron	1.	The	zQ175	line	has	arisen	through	a	spon-
taneous	CAG	 repeat	 expansion	 in	 the	Q140	 line	 (Menalled	et	 al.,	
2012),	and	zQ175	and	Q140	mice	carry	the	same	modifications	to	
F I G U R E  6  Genomic	structures	and	protein	sequence	of	the	genetically	modified	Htt	locus	of	Q140	and	HdhQ150	knock‐in	mice.	(a	and	
b)	Schematics	of	the	mutant	Htt	loci	in	the	HdhQ150	and	Q140	knock‐in	mice.	(a)	In	the	HdhQ150	model,	the	mouse	(CAG)2CAA(CAG)4 
sequence	has	been	replaced	by	an	expanded	CAG	repeat	by	a	double	homologous	recombination	event	that	has	left	no	other	sequence	
modifications	(Lin	et	al.,	2001).	(b)	In	the	Q140	model,	the	XmnI—KpnI	mouse	Htt	sequences	have	been	replaced	with	the	human	XmnI—KpnI	
fragment	(Levine	et	al.,	1999).	This	left	the	amino	acid	sequence	of	the	first	17	amino	acids	before	the	polyQ	repeat	unchanged,	but	the	
amino	acid	sequence	following	the	polyQ	differs	between	human	and	mouse	HTT.	In	addition,	84	bp	at	the	5′	end	of	mouse	intron	1	have	
been	replaced	with	10	bp	from	the	5′	end	of	human	intron	1	and	an	intact	neomycin	resistance	gene	cassette	(neo)	located	1.3	kb	5′	to	the	
initiation	codon.	X	=	XmnI,	K	=	KpnI.	(c)	Alignment	of	the	amino	acid	sequence	of	human	and	mouse	exon	1	HTT.	The	first	17	amino	acids	
before	the	polyQ	repeat	are	identical	in	both	species.	The	polyQ	tract	in	human	HTT	is	followed	by	a	polyproline	(polyP)	repeat,	a	17	amino	
acid	proline‐rich	(P‐rich)	domain,	a	second	polyP	repeat	and	then	12	amino	acids	that	terminate	in	a	proline	residue.	In	comparison,	mouse	
HTT	has	a	6	amino	acid	deletion	in	the	P‐rich	domain	(LLPQPQ),	the	second	polyP	repeat	contains	6	rather	than	10	residues,	a	dipeptide	VA	
deletion	in	the	12	C‐terminal	amino	acids,	as	well	as	four	substitutions	(shown	in	gray).	Neo	=	neomycin
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the	5′	end	of	the	Htt	gene.	We	were	able	to	show	that	the	level	of	
incomplete	 splicing	did	not	differ	between	zQ175	and	zQ175DN,	
in	which	the	neomycin	gene	had	been	removed,	and	therefore	the	
presence	 of	 the	 neo	 was	 unlikely	 to	 underlie	 the	 differences	 in	
splicing	efficiency	between	the	Q140	and	HdhQ150	lines	that	we	
have	identified	in	this	study.	We	have	shown	that	the	splicing	fac-
tor	SRSF6,	which	recognizes	a	CAG	repeat	motif,	binds	to	mutant	
exon	1	mRNA,	and	we	propose	that	this	may	favor	the	incomplete	
splicing	of	exon	1	to	exon2	through	the	ectopic	recruitment	of	the	
U1RNP	spliceosome	complex	(Neueder,	Dumas,	Benjamin,	&	Bates,	
2018).	Incomplete	splicing	could	be	higher	in	the	Q140	line	through	
structural	or	proximity	effects	brought	about	by	human	exon	1,	as	
compared	 to	mouse	exon	1	 sequences.	Alternatively,	 splicing	 en-
hancers	that	are	located	in	the	5′	region	of	intron	1	might	have	been	
deleted	in	the	Q140	line.
The	 exon	 1	HTT	 protein	 has	 been	 shown	 to	 be	 highly	 patho-
genic	in	a	wide	range	of	cellular	and	 in vivo	HD	models	(Barbaro	et	
al.,	2015;	Mangiarini	et	al.,	1996)	and	 is	known	to	aggregate	read-
ily	(Scherzinger	et	al.,	1997).	Of	these,	R6/2	mice	are	transgenic	for	
a	genomic	fragment	that	spans	the	5′	end	of	the	human	HTT	gene	
and	 contains	 promoter	 sequences,	Htt	 exon	 1	 and	 some	 intron	 1	
sequences	 (Mangiarini	 et	 al.,	 1996).	 The	 transgene	 is	 transcribed	
from	the	human	promoter,	through	the	human	exonic	and	 intronic	
sequences	 and	 terminates	 after	 transcribing	 into	mouse	 sequence	
at	the	integration	site.	Therefore,	R6/2	mice	are	a	model	of	the	in-
complete	splicing	that	occurs	in	all	knock‐in	models	of	HD.	There	are	
multiple	studies	that	show	that	late‐stage	disease	phenotypes	that	
develop	in	R6/2	and	knock‐in	mice	are	highly	comparable	(Kuhn	et	
al.,	2007;	Labbadia	et	al.,	2011;	Mielcarek	et	al.,	2014,	2015;	Moffitt,	
McPhail,	Woodman,	Hobbs,	&	Bates,	2009;	Woodman	et	al.,	2007),	
suggesting	that	exon	1	HTT	contributes	to	the	pathogenic	process	
in	these	knock‐in	models.	Our	data	suggest	that	earlier	age	of	onset	
in	Q140	as	compared	to	HdhQ150	mice,	 for	 the	sensorimotor	and	
pathological	 phenotypes	 that	 we	 have	 assessed,	 may	 be	 caused	
by	 the	 increased	 levels	 of	 exon	1	HTT.	However,	 our	 data	do	not	
rule	out	 the	contribution	of	other	 factors,	 for	example,	 the	differ-
ences	between	the	mouse	and	human	polyproline	regions	of	exon	1	
present	 in	HdhQ150	and	Q140,	although	functional	consequences	
of	 these	 sequence	 differences	 at	 the	 protein	 level	 have	 not	 been	
identified,	and	levels	of	full	length	mutant	HTT	have	been	reported	
to	decrease	more	slowly	with	age	 in	HdhQ150	than	 in	Q140	mice	
(Franich	et	al.,	2018).	Nevertheless,	our	data	suggest	that	targeting	
the	production	and/	or	 levels	of	 the	Httexon1	 transcript,	presents	
a	rational	approach	to	complement	existing	therapeutic	strategies.
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